{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-051238","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.098006+00:00","generated_at":"2026-06-03T03:09:05.180533+00:00","sec_items":["1.02","2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Metagenomi ends Moderna collaboration; regains full rights to base editing/RIGS; reports $327.4M cash","bullets":["Mutually terminated 2021 Strategic Collaboration and License Agreement with Moderna as of April 26, 2024.","Metagenomi regains all development/commercialization rights to its wholly-owned base editing and RIGS programs.","No further payments due from Moderna under the termination agreement; future revenue stream eliminated.","Preliminary unaudited cash and cash equivalents of ~$327.4M as of March 31, 2024.","Company will hold an investor call on May 1, 2024, with updated slide presentation (Exhibit 99.1)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-051238","json":"https://secwatch.observer/filing/0000950170-24-051238.json","markdown":"https://secwatch.observer/filing/0000950170-24-051238.md","text":"https://secwatch.observer/filing/0000950170-24-051238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024051238/0000950170-24-051238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024051238/mgx-20240426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:09:05.180533+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08d488ce315ca4920a6d888395104df6827ff0c3","claim":"Metagenomi Therapeutics, Inc. terminated Strategic Collaboration and License Agreement with ModernaTX, Inc. (effective 2024-04-26).","evidence_excerpt":"On April 26, 2024 (the “Termination Date”), Metagenomi, Inc. (the “Company”) and ModernaTX, Inc. (“Moderna”) mutually terminated the Strategic Collaboration and License Agreement dated October 29, 2021 (the “Collaboration Agreement”) by and between the Company and Moderna.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024051238/0000950170-24-051238-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"ModernaTX, Inc."},{"label":"Effective","value":"2024-04-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}